undamentalytics Newsletter
Sign in

Atyr Pharma Inc revenue

Atyr Pharma Inc's revenue was $190,000 in fiscal 2025, down 19.1% on the year before. Since fiscal 2019 ($422,000) it has grown at a compound -12.5% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue010010000
Growth on the year before—+>999%−100.0%—−96.6%−33.4%−19.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Atyr Pharma Inc $190,000 -19.1% -71.9%
Clene Inc. $197,000 -31.1% -36.9%
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Cervomed Inc. $331,295 -95.7% -52.7%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —

Compare with peers

Head to head: ATYR vs CLNNATYR vs CLDXATYR vs CRVO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atyr Pharma Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atyr Pharma Inc.